Key result
Anticoagulation in malignant superior vena cava syndrome was associated with 0% thromboembolic complications (0/15) versus 50% (5/10) without anticoagulation, though 2 fatal hemorrhages occurred.
Why the study?
Does anticoagulation prevent thromboembolic complications in patients with malignant superior vena cava syndrome?
Population
25 patients with malignant superior vena cava syndrome
Comparison
Anticoagulation vs No anticoagulation
Design
Cohort
Authors
Loading...
Anticoagulation was associated with fewer thromboembolic events yet fatal bleeds in malignant SVC syndrome; leaves open net benefit pending randomized trials.
Cohort (n=25)
Does anticoagulation prevent thromboembolic complications in patients with malignant superior vena cava syndrome?
Absolute Event Rate: 0% vs 50%
Anticoagulation may prevent thromboembolic complications in malignant superior vena cava syndrome, but it carries a significant risk of fatal intracranial hemorrhage, underscoring the need for randomized trials.
Adelstein et al. (1988) conducted a cohort in Malignant superior vena cava syndrome (n=25). Anticoagulation vs. No anticoagulation was evaluated on Thromboembolic complications. Anticoagulation in malignant superior vena cava syndrome was associated with 0% thromboembolic complications (0/15) versus 50% (5/10) without anticoagulation, though 2 fatal hemorrhages occurred.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: